Mary Larijani

Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment

Daria Marley Kemp, Alyson Pidich, Mary Larijani et al. · Oncotarget · 2017 · 37 citations · Full text

Different Molecular Defects, Cxcr2 Chemokine Receptors, Immunology +17

Prevalence and Types of Genital Lesions in Organ Transplant Recipients

Kumar S. Nadhan, Mary Larijani, James Abbott et al. · JAMA Dermatology · 2018 · 32 citations · Full text

Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine

Olga Igoucheva, Maddalena Grazzini, Alyson Pidich et al. · Gene Therapy · 2013 · 17 citations · Full text

Vaccination, Tumor Immunology, Orthotopic Melanoma +12

Atopic dermatitis‐like graft‐versus‐host disease treated with dupilumab

Mary Larijani, Diana Zarowin, Anne Wohlschlaeger et al. · Pediatric Dermatology · 2022 · 15 citations

Transplantation, Allergy, Scleroderma +13